Response Pharmaceuticals

RDX‑002 has completed multiple Phase 1 and Phase 1b studies demonstrating safety and efficacy in reducing post-prandial triglycerides, LDL cholesterol, and body weight. The drug achieved its primary endpoint in antipsychotic-induced weight gain in a Phase 1b trial. A Phase 2 study for patients discontinuing GLP‑1 agonists has completed enrollment as of February 2025; results are pending. Across over seven clinical trials with more than 500 subjects dosed up to three months, the compound was well tolerated with mostly mild to moderate GI side effects and no serious adverse events attributed to it.[1][2][5] The company’s approach addresses significant unmet needs both for those experiencing rapid weight regain after stopping GLP‑1 drugs and those suffering from antipsychotic-related metabolic complications.